Trial Profile
An Open-label, Roll-over Study With Rilpivirine in Combination With a Background Regimen Containing Other Antiretrovirals (ARVs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in Rilpivirine Pediatric Studies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Janssen R&D Ireland; Janssen Sciences Ireland UC
- 17 Apr 2024 This trial has been completed in Portugal according to European Clinical Trials Database.
- 26 Mar 2024 Planned End Date changed from 1 Dec 2031 to 31 Dec 2031.
- 26 Mar 2024 Planned primary completion date changed from 1 Dec 2030 to 31 Dec 2030.